Oxford Cancer Biomarkers
Oxford Cancer Biomarkers (OCB) is a biotechnology company founded by University of Oxford professors, Nick La Thangue and David Kerr, to revolutionize cancer clinical decision-making through proprietary biomarker technology. Their products, including ToxNav, OncoProg, and ColoPredict, offer support for clinical decisions by identifying patient risk for chemotherapy toxicity, predicting colorectal cancer relapse, and identifying individuals at higher risk of developing colorectal cancer. OCB leverages AI, digital pathology, and gene analysis to develop these precision diagnostics, aiming to improve patient quality of life, reduce treatment costs, and personalize cancer care. The company has a strong connection to Oxford University and the NHS Trust, and has received an Artificial Intelligence in Health and Care Award.
Oxford Cancer Biomarkers
Oxford Cancer Biomarkers (OCB) is a biotechnology company founded by University of Oxford professors, Nick La Thangue and David Kerr, to revolutionize cancer clinical decision-making through proprietary biomarker technology. Their products, including ToxNav, OncoProg, and ColoPredict, offer support for clinical decisions by identifying patient risk for chemotherapy toxicity, predicting colorectal cancer relapse, and identifying individuals at higher risk of developing colorectal cancer. OCB leverages AI, digital pathology, and gene analysis to develop these precision diagnostics, aiming to improve patient quality of life, reduce treatment costs, and personalize cancer care. The company has a strong connection to Oxford University and the NHS Trust, and has received an Artificial Intelligence in Health and Care Award.